Fapon Showcases AI-Driven Diagnostic Innovations at MEDICA 2025

From November 17 to 20, 2025, the eminent life science company Fapon will exhibit its pioneering diagnostic solutions at MEDICA 2025 in Düsseldorf, Germany. This internationally recognized event serves as a platform to present Fapon's cutting-edge approaches to diagnostics, particularly the integration of artificial intelligence (AI) in developing innovative solutions. The firm's focus at the exhibit will notably spotlight advanced blood test solutions for Alzheimer’s disease (AD), demonstrating how AI technology is facilitating significant advancements in both research and practical applications.

Fapon has introduced a “closed-loop system combining dry and wet testing” in its research and development model. This innovative approach greatly enhances the efficiency with which biomarkers can be discovered and diagnostic solutions can be developed. The centerpiece of this initiative is the cutting-edge AD blood test solution, which is one of the major outcomes derived from this transformative model. Fapon offers diagnostic manufacturers a comprehensive array of raw materials and bulk reagents, targeting critical biomarkers such as p-tau 217, p-tau 181, Amyloid-beta 40, Amyloid-beta 42, GFAP, NfL, and APOE4. What sets these materials apart is their high sensitivity and specificity paired with excellent correlation to reference kits and established clinical diagnostic tests. This ensures that healthcare professionals can develop more accurate and reliable assays for Alzheimer's disease.

In addition to the advanced AD panels, Fapon will showcase its One-Stop IVD solutions, which encompass IVD raw materials, reagent services, and open system instruments. Prominently featured will be the comprehensive chemiluminescence solution. This suite is distinguished by its powerful core raw materials and a panel of more than 70 self-developed assays, alongside the flexible CLIA analysis devices from the Shine i-series, which cater to throughput needs from low to ultra-high. A highlight is the fully automated clinical chemical and immunological analysis system, Shine mT8000, which efficiently automates workflow across a compact area of only 5 m².

Additionally, Fapon will introduce its robust IVD raw materials, which include recombinant materials used for the quality control and calibration of crucial disease markers such as RF, HbA1c, HIV/HIV-P24, HCV, TP, HBV, and ToRCH. These include IgG blockers made without animal-derived components and LAMP solutions meant for rapid molecular diagnostics. The company’s products and services currently reach over 70 countries and regions, partnering with more than 2,500 global collaborators. Fapon is committed to advancing global healthcare by emphasizing technology transfer and supporting local manufacturing initiatives.

Founded to redefine the research and development paradigm in diagnostics and therapeutics, Fapon integrates innovative AI-driven research, diagnostic complete solutions, and novel therapies. This holistic model significantly accelerates the discovery and application of new biomarkers and target molecules, thereby promoting the development of precision medicine. The framework created by Fapon spans the entirety of health management over the entire life cycle, further emphasizing its role in the rapid advancement of precision healthcare.

For those interested in exploring these innovations firsthand, Fapon invites attendees and media alike to visit their booth at MEDICA 2025, further strengthening the dialogue on how AI-led breakthroughs can reshape the future of diagnostics.

To stay connected, Fapon encourages following them on LinkedIn or visiting their official website for more information on their products and services.